{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:57:18Z","timestamp":1794283038355,"version":"4.9.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00816-x","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:27:06Z","timestamp":1786537626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma"],"prefix":"10.1186","volume":"15","author":[{"given":"Callee","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyu Thin","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salyka","family":"Sengsayadeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetola","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Profitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"816_CR1","unstructured":"Teclistamab-cqyv (Tecvayli) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; March 2026."},{"key":"816_CR2","unstructured":"Talquetamab-tgvs (Talvey) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; October 2025."},{"issue":"6","key":"816_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"24","key":"816_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D Bispecific Aantibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"816_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01254-4","volume":"15","author":"F Chunara","year":"2025","unstructured":"Chunara F, Lugo C, Osinski K, et al. Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients. Blood Cancer J. 2025;15(1):61.","journal-title":"Blood Cancer J"},{"issue":"1","key":"816_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01114-7","volume":"14","author":"R Chakraborty","year":"2024","unstructured":"Chakraborty R, Cheruvalath H, Patwari A, et al. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed\/refractory myeloma. Blood Cancer J. 2024;14(1):137.","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"816_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1182\/blood-2023-181228","volume":"142","author":"A Chari","year":"2023","unstructured":"Chari A, Oriol A, Krishnan A, et al. Efficacy and Safety of Less Frequent\/Lower Intensity Dosing of Talquetamab in Patients with Relapsed\/Refractory Multiple Myeloma: Results from the Phase 1\/2 MonumenTAL-1 Study [abstract]. Blood. 2023;142(Supplement 1):1010\u20131.","journal-title":"Blood"},{"issue":"3","key":"816_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11523-026-01205-4","volume":"21","author":"NAQ Card\u00e9","year":"2026","unstructured":"Card\u00e9 NAQ, Niu J, Guo Y, et al. Revised Rrecommendations for R estarting T eclistamab F ollowing D ose D elays: I insights from the MajesTEC-1 S tudy on C clinical S afety, and from Simulated P harmacokinetics and C ytokine D ynamics. Target Oncol. 2026;21(3):373\u201383.","journal-title":"Target Oncol"},{"issue":"13","key":"816_CR9","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/bloodadvances.2024015344","volume":"9","author":"CR Tan","year":"2025","unstructured":"Tan CR, Wang A, Nemirovsky D, et al. Restarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing. Blood Adv. 2025;9(13):3331\u20135.","journal-title":"Blood Adv"},{"issue":"8","key":"816_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","volume":"394","author":"LJ Costa","year":"2026","unstructured":"Costa LJ, Bahlis NJ, Perrot A, et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2026;394(8):739\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"816_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2514752","volume":"394","author":"S Kumar","year":"2026","unstructured":"Kumar S, Mateos MV, Ye JC, et al. Dual Targeting of Extramedullary M yeloma with T alquetamab and T eclistamab. N Engl J Med. 2026;394(1):51\u201361.","journal-title":"N Engl J Med"},{"key":"816_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2604657","author":"R Mina","year":"2026","unstructured":"Mina R, Beksac M, Rodr\u00edguez-Otero P, et al. Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med. 2026. . https:\/\/doi.org\/10.1056\/NEJMoa2604657","journal-title":"N Engl J Med"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00816-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:27:15Z","timestamp":1786537635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00816-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00816-x","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"77"}}